- The ingredients of Gene-Eden-VIR and Novirin are all natural.
- Gene-Eden-VIR and Novirin come in a capsule taken orally.
- Gene-Eden-VIR and Novirin target the latent EBV (Epstein-Barr virus). †
- The clinical study also showed that Gene-Eden-VIR and Novirin are safe (see here, also see details below). †
- Gene-Eden-VIR and Novirin come with a 90 Days Money-Back Guarantee.
- The Gene-Eden-VIR and Novirin formula was developed by analyzing thousands of scientific studies using artificial intelligence (AI).
- Gene-Eden-VIR was launched at the end of 2009, and Novirin in 2014.
- You can choose to take either Gene-Eden-VIR or Novirin. There is no need to take both products at the same time.
FREE Shipping inside the United States
FREE Shipping inside the United States
Gene-Eden-VIR/Novirin is a natural treatment designed to help the immune system target the latent Epstein Barr Virus (EBV). A post marketing clinical study showed that Gene-Eden-VIR/Novirin decreased symptoms of an EBV infection. The study followed the FDA guidelines for clinical studies.
Although the study is written in a language suitable for scientists, we urge you to read the full Gene-Eden-VIR/Novirin clinical study. You can also watch Dr. Hanan Polansky, one of the scientists who conducted the study, explains it.
The following information was published by the Centers for DiseaseControl and Prevention (CDC) on its website. In brackets and italic letters, you can find our comments on the CDC information. Also note our yellow highlights.
Epstein-Barr virus, frequently referred to as EBV, is a member of the herpes virus family and one of the most common human viruses. The virus occurs worldwide, and most people become infected with EBV sometime during their lives. In the United States, as many as 95% of adults between 35 and 40 years of age have been infected. Infants become susceptible to EBV as soon as maternal antibody protection (present at birth) disappears. Many children become infected with EBV, and these infections usually cause no symptoms or are indistinguishable from the other mild, brief illnesses of childhood. In the United States and in other developed countries, many persons are not infected with EBV in their childhood years. When infection with EBV occurs during adolescence or young adulthood, it causes infectious mononucleosis 35% to 50% of the
Symptoms of infectious mononucleosis are fever, sore throat, and swollen lymph glands. Sometimes, a swollen spleen or liver involvement may develop. Heart problems or involvement of the central nervous system occurs only rarely, and infectious mononucleosis is almost never fatal. There are no known associations between active EBV infection and problems during pregnancy, such as miscarriages or birth defects. Although the symptoms of infectious mononucleosis usually resolve in 1 or 2 months, EBV remains in a latent state in a few cells in the throat and blood for the rest of the person’s life. Periodically, the virus can reactivate and is commonly found in the saliva of infected persons. This reactivation usually occurs without symptoms of illness.
EBV also establishes a lifelong latent infection in some cells of the body’s immune system. A late event in a very few carriers of this virus is the emergence of Burkitt’s lymphoma and nasopharyngeal carcinoma, two rare cancers that are not normally found in the United States. EBV appears to play an important role in these malignancies, but is probably not the sole cause of disease.
Most individuals exposed to people with infectious mononucleosis have previously been infected with EBV and are not at risk for infectious mononucleosis. In addition, transmission of EBV requires intimate contact with the saliva (found in the mouth) of an infected person. Transmission of this virus through the air or blood does not normally occur. The incubation period, or the time from infection to appearance of symptoms, ranges from 4 to 6 weeks. Persons with infectious mononucleosis may be able to spread the infection to others for a period of weeks. However, no special precautions or isolation procedures are recommended, since the virus is also found frequently in the saliva of healthy people. In fact, many healthy people can carry and spread the virus intermittently for life. These people are usually the primary reservoir for person-to-person transmission. For this reason, transmission of the virus is almost impossible to prevent.
The clinical diagnosis of infectious mononucleosis is suggested on the basis of the symptoms of fever, sore throat, swollen lymph glands, and the age of the patient. Usually, laboratory tests are needed for confirmation. Serologic results for persons with infectious mononucleosis include an elevated white blood cell count, an increased percentage of certain atypical white blood cells, and a positive reaction to a “mono spot” test.
There is no specific treatment for infectious mononucleosis, other than treating the symptoms. No antiviral drugs or vaccines are available.
[Gene-Eden-VIR/Novirin was designed to help the immune system target latent viruses, including the EBV. A clinical study published in the important medical journal Pharmacology and Pharmacy showed that Gene-Eden-VIR/Novirin decreased the symptoms reported by people suffering from an EBV infection.]
Some physicians have prescribed a 5-day course of steroids to control the swelling of the throat and tonsils. The use of steroids has also been reported to decrease the overall length and severity of illness, but these reports have not been published.
It is important to note that symptoms related to infectious mononucleosis caused by EBV infection seldom last for more than 4 months. When such an illness lasts more than 6 months, it is frequently called chronic EBV infection. However, valid laboratory evidence for continued active EBV infection is seldom found in these patients. The illness should be investigated further to determine if it meets the criteria for chronic fatigue syndrome, or CFS. This process includes ruling out other causes of chronic illness or fatigue.